Start-Up Quarterly Statistics: Fundraising Fell, But Deal-Making Rose In Q3
• By Deanna Kamienski
A review of biopharma start-up deal-making and financing activity from July through September 2017, based on data from Strategic Transactions, showed that fundraising declined 18% from the previous quarter, however the number of acquisitions doubled to eight.
Biopharmaceutical start-up companies – firms founded four years ago or less – raised fewer dollars during the third quarter than during the prior quarter despite Roivant Sciences GMBH's massive $1.1bn equity raise in August.
The slowdown isn't necessarily surprising, since business tends to slow down during the summer months
